Journal of Clinical Oncology, Vol 15, 1518-1528, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial

M Tempero, P Leichner, G Dalrymple, K Harrison, S Augustine, J Schlam, J Anderson, J Wisecarver and D Colcher
Department of Internal Medicine, University of Nebraska, Medical Center, Omaha 68198-6805, USA.

PURPOSE: A phase I trial that evaluated for extrahematopoietic toxicity was conducted with iodine-131 (131I) labeled monoclonal antibody (MAb) CC49. Correlative studies included pharmacokinetic and biodistribution analyses, estimates of absorbed radiation dose, and measurement of human antimonoclonal antibodies (HAMA). PATIENTS AND METHODS: After collection and cryopreservation of hematopoietic stem cells, 15 patients with gastrointestinal cancers were administered a tracer dose of 131I-MAb CC49. Within 5 to 6 days, 14 patients (two to three per activity level) underwent a single treatment with 131I-MAb CC49 (50, 100, 150, 200, 250, and 300 mCi/m2). Biodistribution was determined using planar and single photon emission computer tomographic (SPECT) imaging. Pharmacokinetic studies were performed by measuring radioactivity in serial blood samples. In some patients, biopsies of metastases and related normal tissues were obtained for radioactivity measurements. Radiation dosimetry estimates were calculated using available biodistribution, pharmacokinetic, and tissue biopsy data. Toxicity was evaluated using the National Cancer Institute (NCI) Common Toxicity Criteria. RESULTS: No dose-limiting extrahematopoietic toxicity was identified. Twelve patients experienced grade IV myelosuppression and met criteria for infusion of hematopoietic stem cells. Radioimmunolocalization was excellent. The T1/2 for 131I-MAb CC49 after diagnostic and therapeutic administration was 39.7 +/- 10.4 and 46.1 +/- 10.6 hours, respectively. The percent injected dose per killigram of tumor ranged from 0.2 to 2.1. Absorbed radiation dose in metastatic tumor sites ranged from 630 to 3300 cGy. CONCLUSION: Although extrahematopoietic dose-limiting toxicity was neither observed or predicted, suboptimal absorbed dose estimates suggested that further escalation of 131I-MAb CC49 would not be useful. Future studies should focus on the use of radionuclides with high energy beta emissions, such as yttrium 90, and on strategies to optimize access of antibody to target antigens.

This article has been cited by other articles:

				C. M. Richman, S. J. DeNardo, R. T. O'Donnell, A. Yuan, S. Shen, D. S. Goldstein, J. M. Tuscano, T. Wun, H. K. Chew, P. N. Lara, et al. High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody Clin. Cancer Res., August 15, 2005; 11(16): 5920 - 5927. [Abstract] [Full Text] [PDF]

				S. Shen, S. J. DeNardo, C. M. Richman, A. Yuan, C. H. Siantar, R. T. O'Donnell, L. A. Kroger, and G. L. DeNardo Planning Time for Peripheral Blood Stem Cell Infusion After High-Dose Targeted Radionuclide Therapy Using Dosimetry J. Nucl. Med., June 1, 2005; 46(6): 1034 - 1041. [Abstract] [Full Text] [PDF]

				S. Shen, A. Forero, A. F. LoBuglio, H. Breitz, M.B. Khazaeli, D. R. Fisher, W. Wang, and R. F. Meredith Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC49 Fusion Protein in Patients with Gastrointestinal Malignancies J. Nucl. Med., April 1, 2005; 46(4): 642 - 651. [Abstract] [Full Text] [PDF]

				R. Stein, S. V. Govindan, M. Hayes, G. L. Griffiths, H. J. Hansen, I. D. Horak, and D. M. Goldenberg Advantage of a Residualizing Iodine Radiolabel in the Therapy of a Colon Cancer Xenograft Targeted with an Anticarcinoembryonic Antigen Monoclonal Antibody Clin. Cancer Res., April 1, 2005; 11(7): 2727 - 2734. [Abstract] [Full Text] [PDF]

				R. M. Sharkey and D. M. Goldenberg Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies J. Nucl. Med., January 1, 2005; 46(1_suppl): 115S - 127S. [Abstract] [Full Text] [PDF]

				R. De Pascalis, N. R. Gonzales, E. A. Padlan, P. Schuck, S. K. Batra, J. Schlom, and S. V. S. Kashmiri In Vitro Affinity Maturation of a Specificity-Determining Region-Grafted Humanized Anticarcinoma Antibody: Isolation and Characterization of Minimally Immunogenic High-Affinity Variants Clin. Cancer Res., November 15, 2003; 9(15): 5521 - 5531. [Abstract] [Full Text] [PDF]

				S. S. Graves, E. Dearstyne, Y. Lin, Y. Zuo, J. Sanderson, J. Schultz, A. Pantalias, D. Gray, D. Axworthy, H. M. Jones, et al. Combination Therapy with Pretarget CC49 Radioimmunotherapy and Gemcitabine Prolongs Tumor Doubling Time in a Murine Xenograft Model of Colon Cancer More Effectively Than Either Monotherapy Clin. Cancer Res., September 1, 2003; 9(10): 3712 - 3721. [Abstract] [Full Text] [PDF]

				T. Kurizaki, S. Okazaki, S. D. Sanderson, D. Colcher, C. A. Enke, M. A. Tempero, and J. Baranowska-Kortylewicz Potentiation of Radioimmunotherapy with Response-Selective Peptide Agonist of Human C5a J. Nucl. Med., July 1, 2002; 43(7): 957 - 967. [Abstract] [Full Text] [PDF]

				D. M. Goldenberg Targeted Therapy of Cancer with Radiolabeled Antibodies J. Nucl. Med., May 1, 2002; 43(5): 693 - 713. [Abstract] [Full Text] [PDF]

				A. Goel, S. Augustine, J. Baranowska-Kortylewicz, D. Colcher, B. J. M. Booth, G. Pavlinkova, M. Tempero, and S. K. Batra Single-Dose versus Fractionated Radioimmunotherapy of Human Colon Carcinoma Xenografts Using 131I-labeled Multivalent CC49 Single-chain Fvs Clin. Cancer Res., January 1, 2001; 7(1): 175 - 184. [Abstract] [Full Text]

				M. Tempero, P. Leichner, J. Baranowska-Kortylewicz, K. Harrison, S. Augustine, J. Schlom, J. Anderson, J. Wisecarver, and D. Colcher High-Dose Therapy with 90Yttrium-labeled Monoclonal Antibody CC49: A Phase I Trial Clin. Cancer Res., August 1, 2000; 6(8): 3095 - 3102. [Abstract] [Full Text]

				M. Tamura, D. E. Milenic, M. Iwahashi, E. Padlan, J. Schlom, and S. V. S. Kashmiri Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only J. Immunol., February 1, 2000; 164(3): 1432 - 1441. [Abstract] [Full Text] [PDF]

				G. Pavlinkova, B. J. M. Booth, S. K. Batra, and D. Colcher Radioimmunotherapy of Human Colon Cancer Xenografts Using a Dimeric Single-Chain Fv Antibody Construct Clin. Cancer Res., September 1, 1999; 5(9): 2613 - 2619. [Abstract] [Full Text] [PDF]